About us

Expanding horizons: Identifying targeted opportunities for client brand in the CNS (Central Nervous System) market.

The project identifies where the client’s brand can gain preference within CNS treatment pathways. It focuses commercial investment on the prescribers, follow-up decisions, and care transitions that determine treatment choice and continued use.

Outcome

  • Prioritized patient segments and decision points where the brand’s clinical fit and unmet needs create realistic growth opportunities.
  • Clear prescriber and account priorities, distinguishing who initiates treatment, influences switching, and controls repeat prescribing.
  • Defined positioning and engagement priorities reflecting treatment decisions in hospitals, outpatient clinics, and primary care, alongside patients’ needs at home.
  • Commercial roadmap addressing barriers to adoption and treatment continuity, with actions for prescriber engagement and patient support.

KEY INTELLIGENCE OBJECTIVES

  • Assess addressable demand within the brand’s approved indications, segmented by patient profile, disease severity, treatment stage, and current medication.
  • Map patient pathways from initial symptoms and diagnosis through referral, treatment initiation and ongoing management, identifying delays and points where treatment choices change.
  • Clarify the roles of neurologists, psychiatrists, primary care physicians, and other professionals in recommending treatments, issuing prescriptions, and managing repeat prescriptions.
  • Analyze prescribing habits, including preferred medicines, brand versus molecule prescribing, perceptions of efficacy and tolerability, and willingness to switch patients whose treatment is stable.
  • Examine treatment initiation in hospital and outpatient settings, assessing how discharge recommendations carry into home treatment and who can maintain or change the prescription.
  • Assess the frequency, setting, and purpose of follow-up visits, identifying who reviews response and side effects, and when consultations lead to dose adjustments, switching or prescription renewal.
  • Identify barriers to continued treatment at home, including adverse effects, difficulties managing medication, missed appointments, and gaps in patient or caregiver support.
  • Benchmark competing brands by positioning, formulation, and prescriber engagement.
  • Examine reimbursement, formulary rules, pharmacy substitution, and prescription renewal requirements, assessing how they influence brand access and continuity across care settings.

Geography

  • Europe
  • Middle East
  • Africa
  • North America
  • Latin America
  • Asia-Pacific
  • Global

    • Go back to our case studies

    Get the report

    SUBSCRIBE TO MARKET MINDS

    What matters now. Subscribe to receive intelligence that helps you act before others do.

    Contact us

    Let’s start with a conversation.
    Tell us what you’re facing.

    EMBS GROUP Sp. z o.o. Sp. k., as the Data Administrator, will process the personal data provided above to respond to the message sent via the form. You can contact us at gdpr@embs-group.com or our registered office (Poland, 30-224 Kraków, Aleja Sosnowa 2a).
    The full text of the information clause is available in the Privacy Policy.
    Privacy Overview

    EMBS Group, as the Data Administrator, uses cookies to enhance user experience and analyze website traffic. You can change your cookie settings at any time. For more information, please see our Privacy Policy.